Αρχική World News Adjuvant Selpercatinib Prolongs EFS Among Patients with Stage II or IIIA RET... World News Adjuvant Selpercatinib Prolongs EFS Among Patients with Stage II or IIIA RET Fusion-Positive NSCLC Από Ogkologos - 2 Ιουνίου, 2026 305 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the LIBRETTO-432 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR How to Strengthen Your Immune System: Part 1 17 Σεπτεμβρίου, 2020 An unexpected find: clues about the genetics of children’s cancer found... 6 Απριλίου, 2021 EMA Recommends Extension of Therapeutic Indications for Tisagenlecleucel 4 Μαΐου, 2022 Lymph Node Biopsies Are Unnecessary For Early-Stage Breast Cancer Patients, Study... 7 Ιανουαρίου, 2020 Φόρτωση περισσοτέρων HOT NEWS Reflecting On My Time As the Cancer.Net Editor in Chief Pharmacy services are an untapped resource in tackling nation’s major health... A Third Of Breast Cancer Survivors Have Vaginal Atrophy, But Most... EMA Reminds Physicians to Use Atezolizumab with Nab-paclitaxel for Treating TNBC